In the last trading session, 2.06 million shares of the Lucid Diagnostics Inc (NASDAQ:LUCD) were traded, and its beta was 1.37. Most recently the company’s share price was $1.52, and it changed around -$0.07 or -4.40% from the last close, which brings the market valuation of the company to $164.45M. LUCD currently trades at a discount to its 52-week high of $1.80, offering almost -18.42% off that amount. The share price’s 52-week low was $0.68, which indicates that the current value has risen by an impressive 55.26% since then. We note from Lucid Diagnostics Inc’s average daily trading volume that its 10-day average is 1.33 million shares, with the 3-month average coming to 1.11 million.
Lucid Diagnostics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended LUCD as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Instantly LUCD has showed a red trend with a performance of -4.40% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.7000 on recent trading dayincreased the stock’s daily price by 10.59%. The company’s shares are currently up 85.66% year-to-date, but still up 20.63% over the last five days. On the other hand, Lucid Diagnostics Inc (NASDAQ:LUCD) is 14.29% up in the 30-day period. We can see from the shorts that 1.34 million shares have been sold at a short interest cover period of 0.93 day(s).
The consensus price target as assigned by Wall Street analysts is $2, which translates to bulls needing to increase their stock price by 24.0% from its current value. Analyst projections state that LUCD is forecast to be at a low of $2 and a high of $2.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -54.43%. Lucid Diagnostics Inc earnings are expected to increase by 34.18% in 2025, but the outlook is positive 37.27% per year for the next five years.
LUCD Dividends
Lucid Diagnostics Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 34.55% of Lucid Diagnostics Inc shares, and 9.78% of them are in the hands of institutional investors. The stock currently has a share float of 14.94%. Lucid Diagnostics Inc stock is held by 53.0 institutions, with LUMINUS MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 1.6124% of the shares, which is about 0.73 million shares worth $0.6 million.
VANGUARD GROUP INC, with 1.2461% or 0.56 million shares worth $0.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 366.92 shares worth $0.56 million, making up 0.34% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 193.99 shares worth around $0.29 million, which represents about 0.18% of the total shares outstanding.
